Advancing AI-enabled chemical threat detection and dual-use biodefense technologies through initial commercial deployment
SACRAMENTO, Calif., April 7, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:LNAI), an AI-driven drug discovery and biodefense company, today announced that its subsidiary, BioSymetrics, has entered into a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment, with initial engagement underway and additional engagements currently under discussion.
Under the agreement, BioSymetrics will deploy its proprietary phenotypic screening and artificial intelligence capabilities to enhance the identification, classification, and mechanistic understanding of neuroactive and neurotoxic compounds. The collaboration, structured as a multi-year commercial engagement, represents a key step in expanding Lunai Bioworks' presence in defense and national security applications.
BioSymetrics will implement an integrated approach combining in vivo zebrafish-based phenotypic screening with AI-driven mechanism-of-action (MOA) prediction, enabling rapid hypothesis generation and validation for compounds of interest. This dual capability is designed to accelerate the detection and characterization of chemical threats while improving translational relevance and operational applicability, with screening systems capable of evaluating hundreds to thousands of compounds per week.
Key Components of the Collaboration:
- Experimental screening of chemical compounds with a focus on central nervous system-active agents
- AI-based computational modeling to predict mechanisms of action and identify novel or unknown threats
- Integration of biological and computational datasets to improve identification of neuroactive and toxic compounds and enhance readiness
- Support for defense-oriented partnership pathways and interoperability across allied research frameworks